AstraZeneca and Saint Luke’s Mid America Heart Institute announced high-level results of the DARE-19 Phase III trial assessing the potential of Farxiga to treat patients hospitalized with COVID-19 who are at risk of developing serious complications.
The companies confirmed on April 12, 2021, this trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality and the primary endpoint of recovery measuring a change in clinical status (from early recovery to death) at 30 days.
Diabetes Drug Found Ineffective Against COVID-19
Skin Reactions Usually Mild After COVID-19 Vaccination
Most common were delayed large local reactions, followed by local injection site reactions, urticarial eruptions, morbilliform eruptions
Blood Clot Risk High Following COVID-19 Hospitalization
However, anticoagulation cuts risk for major thromboembolic events by 46 percent
Dialysis Patients Develop Lower Antibody Response to Pfizer COVID-19 Vaccine
Response is lower than for individuals without kidney disease, and age affects response regardless of medical conditions
FDA to Decide ‘Quickly’ on Pfizer Request to Approve COVID-19 Vaccine for Children 12 to 15
Currently, the FDA allows the Pfizer vaccine to be given to people 16 years and older
Antibody Cocktail May Curb Infection in Unvaccinated Exposed to COVID-19
Drug company will ask FDA to expand the drug’s EUA to allow it to be given for preventive purposes in ‘appropriate populations’
Scammers Selling Fake COVID-19 Vaccination Cards
Fakespot, which identifies online retail scams, has pinpointed hundreds of different sellers of fake vaccination cards since the start of the year
Chinese COVID-19 Vaccines Not Very Effective: Official
Effectiveness of one vaccine at preventing symptomatic infections was found to be as low as 50.4 percent by researchers in Brazil